VolitionRx Q1 Revenue $1M, DETECSEPS Patient Target September

VolitionRx reported Q1 2026 revenue of about $1 million and ended the quarter with $3.1 million in cash. The diagnostics developer also guided for the first patient enrollment in its DETECSEPS sepsis test program in September, setting up a catalyst timeline that investors will measure against cash runway.

Q1 2026: Revenue and Cash Position

The $1 million revenue figure reflects VolitionRx’s early-stage commercial footprint, primarily from its Nu.Q Vet veterinary diagnostics and ongoing partnership work with Fuji. For a development-stage company, that top line is modest. The $3.1 million cash balance is the more immediate constraint. Without a near-term infusion, the company’s ability to fund operations through multiple catalyst events depends on hitting milestone payments. VolitionRx has flagged a $5 million milestone tied to one of its pipeline programs, though the exact trigger has not been specified. That payment, if received, would meaningfully extend the runway.

DETECSEPS Patient Enrollment as Key Catalyst

The DETECSEPS test targets sepsis, a large and underserved diagnostic market. VolitionRx expects to enroll the first patient in September. That milestone is a proof-of-concept event: successful enrollment would demonstrate that the company can execute on its clinical plan and move toward regulatory validation. For investors, the September date is the next concrete decision point. If enrollment proceeds on schedule, it reduces the risk that the program is stalled. A delay, however, would put pressure on the cash position and raise the likelihood of dilutive financing.

Pipeline Catalysts and Milestone Timing

Beyond DETECSEPS, VolitionRx has multiple irons in the fire. The Nu.Q Vet platform is already generating revenue through the Fuji partnership, and the company continues to develop a lung cancer diagnostic. The $5 million milestone – likely tied to a licensing or partnership trigger – could come from any of these programs. The timing of that payment is critical. If it arrives before the cash balance runs low, VolitionRx can fund operations without issuing new equity. If it slips, the company may need to raise capital at unfavorable terms.

For broader context on how biotech earnings and catalyst timelines interact, see our stock market analysis. Investors tracking small-cap diagnostics should also review the best stock brokers for trading these names.

The September DETECSEPS enrollment date is the single most important near-term marker. A successful enrollment would validate the clinical path and potentially unlock the $5 million milestone. A miss would force VolitionRx to either cut spending or seek external funding. Either way, the next six months will define the company’s financial trajectory.